#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acute promyelocytic leukaemia Autoimmune haemolytic anaemia Leukaemia Hepato-lenticular degeneration Acute lymphocytic leukaemia Graft versus host disease Oropharyngeal cancer recurrent Blood iron increased Amyotrophic lateral sclerosis gene carrier Mucous membrane pemphigoid Familial dilated cardiomyopathy Cutaneous T-cell lymphoma Anti-neutrophil cytoplasmic antibody positive vasculitis Breast angiosarcoma Familial amyotrophic lateral sclerosis More trials…

    Learn about Rare Diseases

    Crigler-Najjar syndrome – Basic Information Hepatoblastoma – Trials in Disease Angiosarcoma non-metastatic Glomerulonephritis membranoproliferative – Treatment Hyperoxaluria – Life with Disease Basal cell naevus syndrome – Trials in Disease Piriformis syndrome – Diagnostics Ewing’s sarcoma recurrent – Trials in Disease Pemphigus – Basic Information Congenital hypotransferrinaemia – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    ULTEVURSEN Elezanumab Gs-5718-03 Prednisolone Sodium Succinate Morf-057 Lisinopril Dihydrate Jnj-81241459 Munc-T3 Cholic Acid Suxamethonium Chloride Dorzolamide Hydrochloride Donidalorsen Methylphenidate Hydrochloride ASP2957 Tenofovir Disoproxil Fumarate Siponimod Betamethasone Bt-001 ANX007 S-241656 More therapies…

    Learn about Your Condition

    Cutaneous sarcoidosis Thrombotic microangiopathy Reperfusion injury Hepatobiliary cancer Gastrooesophageal cancer Oesophageal adenocarcinoma Intracranial aneurysm Toxic epidermal necrolysis Bone marrow failure T-cell type acute leukaemia Embolism venous Mucopolysaccharidosis II Morning sickness Acute promyelocytic leukaemia Hydrocephalus More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Pleural mesothelioma malignant

  • Study of Ivonescimab for Treating Relapsed Pleural Mesothelioma in Patients After Immunotherapy and Chemotherapy

    Recruiting

    2 1 1
    Investigated Diseases:
    • Pleural mesothelioma malignant
    Investigated Drugs:
    • Ivonescimab
    France

  • Study on Neoadjuvant Chemotherapy and Immunotherapy with Ipilimumab, Pemetrexed, and Drug Combination for Patients with Inoperable Pleural Mesothelioma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Pleural mesothelioma malignant
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Ipilimumab
    Belgium

  • Study on Atezolizumab for Patients with Malignant Pleural Mesothelioma After Surgery

    Recruiting

    3 1 1
    Investigated Diseases:
    • Pleural mesothelioma malignant
    Investigated Drugs:
    • Atezolizumab
    Italy

  • Study of Tremelimumab for Patients with Unresectable Malignant Mesothelioma

    Recruiting

    2 1
    Investigated Diseases:
    • Pleural mesothelioma malignant
    • Peritoneal mesothelioma malignant
    Investigated Drugs:
    • Tremelimumab
    Italy

  • Study of Intrapleural Photodynamic Therapy with Aminolevulinic Acid Hydrochloride and Nivolumab for Patients with Malignant Pleural Mesothelioma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Pleural mesothelioma malignant
    Investigated Drugs:
    • Aminolevulinic Acid Hydrochloride
    • Nivolumab
    France

  • Study on Adding Atezolizumab and WT1/DC Vaccine to Standard Treatment for Patients with Epithelioid Malignant Pleural Mesothelioma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Pleural mesothelioma malignant
    Investigated Drugs:
    • Wt1 Lamp Mrna Dc
    • Atezolizumab
    Belgium
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!